{"transactions":[{"id":677087,"issuer":{"id":6339,"kind":"organization","name":"Alpha Cognition Inc.","symbol":"ACOG"},"owners":[{"id":20237,"kind":"person","name":"Wills Robert James","position":1,"cik":"0001634189","reported_name":"Wills Robert James","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Shares","published_at":"2026-08-24T18:52:45.000Z","date":"2026-08-21","kind":"purchase","planned":false,"acquired":true,"shares":10000,"price":9.62,"value":96200.0,"ownership":{"direct":true},"balance_after":32241,"source":{"system":"sec-edgar","filing":"0000912282-26-001153","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1634189/000091228226001153/form4.xml","form_type":"4"}},{"id":739305,"issuer":{"id":6561,"kind":"organization","name":"Milestone Pharmaceuticals Inc."},"owners":[{"id":20237,"kind":"person","name":"Wills Robert James","position":1,"cik":"0001634189","reported_name":"Wills Robert James","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-06-12T20:15:20.000Z","date":"2026-06-10","kind":"grant","planned":false,"acquired":true,"shares":77000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option will vest in twelve (12) equal monthly installments, beginning on July 10, 2026, provided that the option will in any case be fully vested on the date of next annual meeting of the stockholders of the Issuer, subject to the Reporting Person continuing to provide service through each such vesting date."}],"balance_after":77000,"derivative":{"exercise_price":1.22,"expiration_date":"2036-06-10","underlying":"Common Stock","underlying_shares":77000},"source":{"system":"sec-edgar","filing":"0001634189-26-000002","document":"form4-06122026_040601.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1408443/000163418926000002/form4-06122026_040601.xml","form_type":"4"}},{"id":936741,"issuer":{"id":6339,"kind":"organization","name":"Alpha Cognition Inc.","symbol":"ACOG"},"owners":[{"id":20237,"kind":"person","name":"Wills Robert James","position":1,"cik":"0001634189","reported_name":"Wills Robert James","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Share Options","published_at":"2026-01-16T21:21:43.000Z","date":"2026-01-14","kind":"grant","planned":false,"acquired":true,"shares":8437,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The options will vest one year from date of grant."}],"balance_after":8437,"derivative":{"exercise_price":6.56,"expiration_date":"2036-01-14","underlying":"Common Shares","underlying_shares":8437},"source":{"system":"sec-edgar","filing":"0000912282-26-000070","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1634189/000091228226000070/form4.xml","form_type":"4"}},{"id":936740,"issuer":{"id":6339,"kind":"organization","name":"Alpha Cognition Inc.","symbol":"ACOG"},"owners":[{"id":20237,"kind":"person","name":"Wills Robert James","position":1,"cik":"0001634189","reported_name":"Wills Robert James","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Shares","published_at":"2026-01-16T21:21:43.000Z","date":"2026-01-14","kind":"grant","planned":false,"acquired":true,"shares":7241,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Restricted stock units that vest one year from date of grant."}],"balance_after":22241,"source":{"system":"sec-edgar","filing":"0000912282-26-000070","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1634189/000091228226000070/form4.xml","form_type":"4"}},{"id":1059029,"issuer":{"id":6339,"kind":"organization","name":"Alpha Cognition Inc.","symbol":"ACOG"},"owners":[{"id":20237,"kind":"person","name":"Wills Robert James","position":1,"cik":"0001634189","reported_name":"Wills Robert James","relationship":{"director":true}}],"security":"Common Stock","published_at":"2025-08-21T16:36:53.000Z","date":"2025-08-18","kind":"purchase","planned":false,"acquired":true,"shares":15000,"price":8.4885,"value":127327.5,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Open market purchase."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The reported price in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $8.15 to $8.86 per share. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote."}],"balance_after":15000,"source":{"system":"sec-edgar","filing":"0000912282-25-000893","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1634189/000091228225000893/form4.xml","form_type":"4"}},{"id":1087244,"issuer":{"id":6561,"kind":"organization","name":"Milestone Pharmaceuticals Inc."},"owners":[{"id":20237,"kind":"person","name":"Wills Robert James","position":1,"cik":"0001634189","reported_name":"Wills Robert James","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Series B Common Warrants (right to buy)","published_at":"2025-07-15T20:15:23.000Z","date":"2025-07-11","kind":"grant","planned":false,"acquired":true,"shares":50000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The reported securities are included within 50,000 Issuer Units purchased by the Reporting Person for $1.50 per Unit. Each Unit consists of one common share, one Series A common warrant and one Series B common warrant, each warrant represents the right to purchase 50,000 shares of common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Fully vested and exercisable."}],"balance_after":50000,"derivative":{"exercise_price":1.875,"expiration_date":"2030-07-11","underlying":"Common Shares","underlying_shares":50000},"source":{"system":"sec-edgar","filing":"0001415889-25-019774","document":"form4-07152025_040719.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1408443/000141588925019774/form4-07152025_040719.xml","form_type":"4"}},{"id":1087243,"issuer":{"id":6561,"kind":"organization","name":"Milestone Pharmaceuticals Inc."},"owners":[{"id":20237,"kind":"person","name":"Wills Robert James","position":1,"cik":"0001634189","reported_name":"Wills Robert James","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Series A Common Warrants (right to buy)","published_at":"2025-07-15T20:15:23.000Z","date":"2025-07-11","kind":"grant","planned":false,"acquired":true,"shares":50000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The reported securities are included within 50,000 Issuer Units purchased by the Reporting Person for $1.50 per Unit. Each Unit consists of one common share, one Series A common warrant and one Series B common warrant, each warrant represents the right to purchase 50,000 shares of common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Fully vested and exercisable."}],"balance_after":50000,"derivative":{"exercise_price":1.5,"expiration_date":"2026-07-11","underlying":"Common Shares","underlying_shares":50000},"source":{"system":"sec-edgar","filing":"0001415889-25-019774","document":"form4-07152025_040719.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1408443/000141588925019774/form4-07152025_040719.xml","form_type":"4"}},{"id":1087242,"issuer":{"id":6561,"kind":"organization","name":"Milestone Pharmaceuticals Inc."},"owners":[{"id":20237,"kind":"person","name":"Wills Robert James","position":1,"cik":"0001634189","reported_name":"Wills Robert James","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Shares","published_at":"2025-07-15T20:15:23.000Z","date":"2025-07-11","kind":"grant","planned":false,"acquired":true,"shares":50000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The reported securities are included within 50,000 Issuer Units purchased by the Reporting Person for $1.50 per Unit. Each Unit consists of one common share, one Series A common warrant and one Series B common warrant, each warrant represents the right to purchase 50,000 shares of common stock."}],"balance_after":65000,"source":{"system":"sec-edgar","filing":"0001415889-25-019774","document":"form4-07152025_040719.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1408443/000141588925019774/form4-07152025_040719.xml","form_type":"4"}},{"id":1112965,"issuer":{"id":6561,"kind":"organization","name":"Milestone Pharmaceuticals Inc."},"owners":[{"id":20237,"kind":"person","name":"Wills Robert James","position":1,"cik":"0001634189","reported_name":"Wills Robert James","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2025-06-12T20:19:05.000Z","date":"2025-06-10","kind":"grant","planned":false,"acquired":true,"shares":40000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option will vest in twelve (12) equal monthly installments, beginning on July 10, 2025, provided that the option will in any case be fully vested on the date of next annual meeting of the stockholders of the Issuer, subject to the Reporting Person continuing to provide service through each such vesting date."}],"balance_after":40000,"derivative":{"exercise_price":1.75,"expiration_date":"2035-06-10","underlying":"Common Stock","underlying_shares":40000},"source":{"system":"sec-edgar","filing":"0001415889-25-016935","document":"form4-06122025_040616.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1408443/000141588925016935/form4-06122025_040616.xml","form_type":"4"}},{"id":1174547,"issuer":{"id":6339,"kind":"organization","name":"Alpha Cognition Inc.","symbol":"ACOG"},"owners":[{"id":20237,"kind":"person","name":"Wills Robert James","position":1,"cik":"0001634189","reported_name":"Wills Robert James","relationship":{"director":true}}],"security":"Director Stock Option (Right to Buy)","published_at":"2025-04-10T01:44:29.000Z","date":"2025-04-07","kind":"grant","planned":false,"acquired":true,"shares":30019,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The options will vest over 24 months, with 12.5% vesting on the grant date and remainder to vest 12.5% per quarter thereafter."}],"balance_after":30019,"derivative":{"exercise_price":4.43,"expiration_date":"2025-04-07","underlying":"Common Shares","underlying_shares":30019},"source":{"system":"sec-edgar","filing":"0000912282-25-000390","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1634189/000091228225000390/form4.xml","form_type":"4"}},{"id":1419769,"issuer":{"id":6561,"kind":"organization","name":"Milestone Pharmaceuticals Inc."},"owners":[{"id":20237,"kind":"person","name":"Wills Robert James","position":1,"cik":"0001634189","reported_name":"Wills Robert James","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2024-08-29T20:15:11.000Z","date":"2024-08-28","kind":"grant","planned":false,"acquired":true,"shares":40000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option will vest in twelve (12) equal monthly installments, beginning on September 28, 2024, provided that the option will in any case be fully vested on the date of next annual meeting of the stockholders of the Issuer, subject to the Reporting Person continuing to provide service through each such vesting date."}],"balance_after":40000,"derivative":{"exercise_price":1.45,"expiration_date":"2034-08-28","underlying":"Common Shares","underlying_shares":40000},"source":{"system":"sec-edgar","filing":"0001415889-24-022532","document":"form4-08292024_040801.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1408443/000141588924022532/form4-08292024_040801.xml","form_type":"4"}},{"id":1470516,"issuer":{"id":89585,"kind":"organization","name":"Oncternal Therapeutics, Inc.","symbol":"ONCT"},"owners":[{"id":20237,"kind":"person","name":"Wills Robert James","position":1,"cik":"0001634189","reported_name":"Wills Robert James","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Options","published_at":"2024-06-24T16:05:11.000Z","date":"2024-06-20","kind":"grant","planned":false,"acquired":true,"shares":2200,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"One-twelfth of the number of shares subject to the option vest and become exercisable in substantially equal installments on each monthly anniversary of the grant date, subject to the Reporting Person's continued service through such vesting date."}],"balance_after":2200,"derivative":{"exercise_price":8.1,"expiration_date":"2034-06-20","underlying":"Common Stock","underlying_shares":2200},"source":{"system":"sec-edgar","filing":"0000950170-24-076700","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1260990/000095017024076700/ownership.xml","form_type":"4"}},{"id":1543629,"issuer":{"id":89585,"kind":"organization","name":"Oncternal Therapeutics, Inc.","symbol":"ONCT"},"owners":[{"id":20237,"kind":"person","name":"Wills Robert James","position":1,"cik":"0001634189","reported_name":"Wills Robert James","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-04-10T20:38:22.000Z","date":"2024-04-08","kind":"purchase","planned":false,"acquired":true,"shares":3086,"price":8.9613,"value":27654.5718,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The common stock purchase is matchable under Section 16(b) of the Securities Exchange Act of 1934, but the reporting person previously paid the Issuer the full amount of the profit realized in connection with the short swing transaction. No further amounts are required to be disgorged."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The reported price is a weighted-average price. These shares were purchased in multiple transactions at prices ranging from $8.76 to $9.00. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer or the SEC Staff, upon request, full information regarding the number of shares purchased at each price within the range set forth above."}],"balance_after":10000,"source":{"system":"sec-edgar","filing":"0001209191-24-005283","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1260990/000120919124005283/doc4.xml","form_type":"4"}},{"id":1556074,"issuer":{"id":89585,"kind":"organization","name":"Oncternal Therapeutics, Inc.","symbol":"ONCT"},"owners":[{"id":20237,"kind":"person","name":"Wills Robert James","position":1,"cik":"0001634189","reported_name":"Wills Robert James","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-04-01T19:00:13.000Z","date":"2024-03-28","kind":"purchase","planned":false,"acquired":true,"shares":6914,"price":8.4759,"value":58602.3726,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The Reporting Person's common stock purchase is matchable under Section 16(b) of the Securities Exchange Act of 1934, to the extent of 980 shares at a weighted average price per share of $8.1548, with the sale of 980 shares of common stock at a price per share of $9.04 on February 23, 2024. The Reporting Person has agreed to pay the issuer $867.51, representing the full amount of the profit realized in connection with the short-swing transaction."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The reported price is a weighted-average price. These shares were purchased in multiple transactions at prices ranging from $8.095 to $9.00. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer or the SEC Staff, upon request, full information regarding the number of shares purchased at each price within the range set forth above."}],"balance_after":6914,"source":{"system":"sec-edgar","filing":"0001209191-24-005154","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1260990/000120919124005154/doc4.xml","form_type":"4"}},{"id":1563837,"issuer":{"id":92768,"kind":"organization","name":"CymaBay Therapeutics, Inc.","symbol":"CBAY"},"owners":[{"id":20237,"kind":"person","name":"Wills Robert James","position":1,"cik":"0001634189","reported_name":"Wills Robert James","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Employee Stock Option (right to buy)","published_at":"2024-03-22T16:55:35.000Z","date":"2024-03-22","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":14010,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Pursuant to the Merger Agreement, each outstanding CymaBay stock option, whether or not vested, was cancelled and converted into the right to receive a cash payment equal to the product of (a) the excess of (i) $32.50 over (ii) the per share exercise price of such stock option, and (b) the total number of shares of CymaBay common stock subject to such stock option immediately prior to the effective time of the Merger, less applicable withholding taxes.  Any outstanding CymaBay stock option with an exercise price equal to or greater than $32.50 was canceled for no consideration."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Pursuant to the Merger Agreement, each outstanding CymaBay stock option, whether or not vested, was cancelled and converted into the right to receive a cash payment equal to the product of (a) the excess of (i) $32.50 over (ii) the per share exercise price of such stock option, and (b) the total number of shares of CymaBay common stock subject to such stock option immediately prior to the effective time of the Merger, less applicable withholding taxes.  Any outstanding CymaBay stock option with an exercise price equal to or greater than $32.50 was canceled for no consideration."}],"balance_after":0,"derivative":{"exercise_price":22.85,"expiration_date":"2034-01-23","underlying":"Common Stock","underlying_shares":14010},"source":{"system":"sec-edgar","filing":"0000950170-24-035448","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":14,"url":"https://www.sec.gov/Archives/edgar/data/1042074/000095017024035448/ownership.xml","form_type":"4"}},{"id":1563836,"issuer":{"id":92768,"kind":"organization","name":"CymaBay Therapeutics, Inc.","symbol":"CBAY"},"owners":[{"id":20237,"kind":"person","name":"Wills Robert James","position":1,"cik":"0001634189","reported_name":"Wills Robert James","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Employee Stock Option (right to buy)","published_at":"2024-03-22T16:55:35.000Z","date":"2024-03-22","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":25000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Pursuant to the Merger Agreement, each outstanding CymaBay stock option, whether or not vested, was cancelled and converted into the right to receive a cash payment equal to the product of (a) the excess of (i) $32.50 over (ii) the per share exercise price of such stock option, and (b) the total number of shares of CymaBay common stock subject to such stock option immediately prior to the effective time of the Merger, less applicable withholding taxes.  Any outstanding CymaBay stock option with an exercise price equal to or greater than $32.50 was canceled for no consideration."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Pursuant to the Merger Agreement, each outstanding CymaBay stock option, whether or not vested, was cancelled and converted into the right to receive a cash payment equal to the product of (a) the excess of (i) $32.50 over (ii) the per share exercise price of such stock option, and (b) the total number of shares of CymaBay common stock subject to such stock option immediately prior to the effective time of the Merger, less applicable withholding taxes.  Any outstanding CymaBay stock option with an exercise price equal to or greater than $32.50 was canceled for no consideration."}],"balance_after":0,"derivative":{"exercise_price":7.8,"expiration_date":"2033-01-24","underlying":"Common Stock","underlying_shares":25000},"source":{"system":"sec-edgar","filing":"0000950170-24-035448","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":13,"url":"https://www.sec.gov/Archives/edgar/data/1042074/000095017024035448/ownership.xml","form_type":"4"}},{"id":1563835,"issuer":{"id":92768,"kind":"organization","name":"CymaBay Therapeutics, Inc.","symbol":"CBAY"},"owners":[{"id":20237,"kind":"person","name":"Wills Robert James","position":1,"cik":"0001634189","reported_name":"Wills Robert James","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Employee Stock Option (right to buy)","published_at":"2024-03-22T16:55:35.000Z","date":"2024-03-22","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":67000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Pursuant to the Merger Agreement, each outstanding CymaBay stock option, whether or not vested, was cancelled and converted into the right to receive a cash payment equal to the product of (a) the excess of (i) $32.50 over (ii) the per share exercise price of such stock option, and (b) the total number of shares of CymaBay common stock subject to such stock option immediately prior to the effective time of the Merger, less applicable withholding taxes.  Any outstanding CymaBay stock option with an exercise price equal to or greater than $32.50 was canceled for no consideration."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Pursuant to the Merger Agreement, each outstanding CymaBay stock option, whether or not vested, was cancelled and converted into the right to receive a cash payment equal to the product of (a) the excess of (i) $32.50 over (ii) the per share exercise price of such stock option, and (b) the total number of shares of CymaBay common stock subject to such stock option immediately prior to the effective time of the Merger, less applicable withholding taxes.  Any outstanding CymaBay stock option with an exercise price equal to or greater than $32.50 was canceled for no consideration."}],"balance_after":0,"derivative":{"exercise_price":2.94,"expiration_date":"2032-01-24","underlying":"Common Stock","underlying_shares":67000},"source":{"system":"sec-edgar","filing":"0000950170-24-035448","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":12,"url":"https://www.sec.gov/Archives/edgar/data/1042074/000095017024035448/ownership.xml","form_type":"4"}},{"id":1563834,"issuer":{"id":92768,"kind":"organization","name":"CymaBay Therapeutics, Inc.","symbol":"CBAY"},"owners":[{"id":20237,"kind":"person","name":"Wills Robert James","position":1,"cik":"0001634189","reported_name":"Wills Robert James","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Employee Stock Option (right to buy)","published_at":"2024-03-22T16:55:35.000Z","date":"2024-03-22","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":32000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Pursuant to the Merger Agreement, each outstanding CymaBay stock option, whether or not vested, was cancelled and converted into the right to receive a cash payment equal to the product of (a) the excess of (i) $32.50 over (ii) the per share exercise price of such stock option, and (b) the total number of shares of CymaBay common stock subject to such stock option immediately prior to the effective time of the Merger, less applicable withholding taxes.  Any outstanding CymaBay stock option with an exercise price equal to or greater than $32.50 was canceled for no consideration."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Pursuant to the Merger Agreement, each outstanding CymaBay stock option, whether or not vested, was cancelled and converted into the right to receive a cash payment equal to the product of (a) the excess of (i) $32.50 over (ii) the per share exercise price of such stock option, and (b) the total number of shares of CymaBay common stock subject to such stock option immediately prior to the effective time of the Merger, less applicable withholding taxes.  Any outstanding CymaBay stock option with an exercise price equal to or greater than $32.50 was canceled for no consideration."}],"balance_after":0,"derivative":{"exercise_price":5.78,"expiration_date":"2031-01-25","underlying":"Common Stock","underlying_shares":32000},"source":{"system":"sec-edgar","filing":"0000950170-24-035448","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/1042074/000095017024035448/ownership.xml","form_type":"4"}},{"id":1563833,"issuer":{"id":92768,"kind":"organization","name":"CymaBay Therapeutics, Inc.","symbol":"CBAY"},"owners":[{"id":20237,"kind":"person","name":"Wills Robert James","position":1,"cik":"0001634189","reported_name":"Wills Robert James","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Employee Stock Option (right to buy)","published_at":"2024-03-22T16:55:35.000Z","date":"2024-03-22","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":49245,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Pursuant to the Merger Agreement, each outstanding CymaBay stock option, whether or not vested, was cancelled and converted into the right to receive a cash payment equal to the product of (a) the excess of (i) $32.50 over (ii) the per share exercise price of such stock option, and (b) the total number of shares of CymaBay common stock subject to such stock option immediately prior to the effective time of the Merger, less applicable withholding taxes.  Any outstanding CymaBay stock option with an exercise price equal to or greater than $32.50 was canceled for no consideration."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Pursuant to the Merger Agreement, each outstanding CymaBay stock option, whether or not vested, was cancelled and converted into the right to receive a cash payment equal to the product of (a) the excess of (i) $32.50 over (ii) the per share exercise price of such stock option, and (b) the total number of shares of CymaBay common stock subject to such stock option immediately prior to the effective time of the Merger, less applicable withholding taxes.  Any outstanding CymaBay stock option with an exercise price equal to or greater than $32.50 was canceled for no consideration."}],"balance_after":0,"derivative":{"exercise_price":4.05,"expiration_date":"2030-05-14","underlying":"Common Stock","underlying_shares":49245},"source":{"system":"sec-edgar","filing":"0000950170-24-035448","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1042074/000095017024035448/ownership.xml","form_type":"4"}},{"id":1563832,"issuer":{"id":92768,"kind":"organization","name":"CymaBay Therapeutics, Inc.","symbol":"CBAY"},"owners":[{"id":20237,"kind":"person","name":"Wills Robert James","position":1,"cik":"0001634189","reported_name":"Wills Robert James","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Employee Stock Option (right to buy)","published_at":"2024-03-22T16:55:35.000Z","date":"2024-03-22","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":27705,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Pursuant to the Merger Agreement, each outstanding CymaBay stock option, whether or not vested, was cancelled and converted into the right to receive a cash payment equal to the product of (a) the excess of (i) $32.50 over (ii) the per share exercise price of such stock option, and (b) the total number of shares of CymaBay common stock subject to such stock option immediately prior to the effective time of the Merger, less applicable withholding taxes.  Any outstanding CymaBay stock option with an exercise price equal to or greater than $32.50 was canceled for no consideration."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Pursuant to the Merger Agreement, each outstanding CymaBay stock option, whether or not vested, was cancelled and converted into the right to receive a cash payment equal to the product of (a) the excess of (i) $32.50 over (ii) the per share exercise price of such stock option, and (b) the total number of shares of CymaBay common stock subject to such stock option immediately prior to the effective time of the Merger, less applicable withholding taxes.  Any outstanding CymaBay stock option with an exercise price equal to or greater than $32.50 was canceled for no consideration."}],"balance_after":0,"derivative":{"exercise_price":8.43,"expiration_date":"2029-01-28","underlying":"Common Stock","underlying_shares":27705},"source":{"system":"sec-edgar","filing":"0000950170-24-035448","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1042074/000095017024035448/ownership.xml","form_type":"4"}},{"id":1563831,"issuer":{"id":92768,"kind":"organization","name":"CymaBay Therapeutics, Inc.","symbol":"CBAY"},"owners":[{"id":20237,"kind":"person","name":"Wills Robert James","position":1,"cik":"0001634189","reported_name":"Wills Robert James","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Employee Stock Option (right to buy)","published_at":"2024-03-22T16:55:35.000Z","date":"2024-03-22","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":16000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Pursuant to the Merger Agreement, each outstanding CymaBay stock option, whether or not vested, was cancelled and converted into the right to receive a cash payment equal to the product of (a) the excess of (i) $32.50 over (ii) the per share exercise price of such stock option, and (b) the total number of shares of CymaBay common stock subject to such stock option immediately prior to the effective time of the Merger, less applicable withholding taxes.  Any outstanding CymaBay stock option with an exercise price equal to or greater than $32.50 was canceled for no consideration."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Pursuant to the Merger Agreement, each outstanding CymaBay stock option, whether or not vested, was cancelled and converted into the right to receive a cash payment equal to the product of (a) the excess of (i) $32.50 over (ii) the per share exercise price of such stock option, and (b) the total number of shares of CymaBay common stock subject to such stock option immediately prior to the effective time of the Merger, less applicable withholding taxes.  Any outstanding CymaBay stock option with an exercise price equal to or greater than $32.50 was canceled for no consideration."}],"balance_after":0,"derivative":{"exercise_price":11.69,"expiration_date":"2028-01-23","underlying":"Common Stock","underlying_shares":16000},"source":{"system":"sec-edgar","filing":"0000950170-24-035448","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1042074/000095017024035448/ownership.xml","form_type":"4"}},{"id":1563830,"issuer":{"id":92768,"kind":"organization","name":"CymaBay Therapeutics, Inc.","symbol":"CBAY"},"owners":[{"id":20237,"kind":"person","name":"Wills Robert James","position":1,"cik":"0001634189","reported_name":"Wills Robert James","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Employee Stock Option (right to buy)","published_at":"2024-03-22T16:55:35.000Z","date":"2024-03-22","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":7500,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Pursuant to the Merger Agreement, each outstanding CymaBay stock option, whether or not vested, was cancelled and converted into the right to receive a cash payment equal to the product of (a) the excess of (i) $32.50 over (ii) the per share exercise price of such stock option, and (b) the total number of shares of CymaBay common stock subject to such stock option immediately prior to the effective time of the Merger, less applicable withholding taxes.  Any outstanding CymaBay stock option with an exercise price equal to or greater than $32.50 was canceled for no consideration."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Pursuant to the Merger Agreement, each outstanding CymaBay stock option, whether or not vested, was cancelled and converted into the right to receive a cash payment equal to the product of (a) the excess of (i) $32.50 over (ii) the per share exercise price of such stock option, and (b) the total number of shares of CymaBay common stock subject to such stock option immediately prior to the effective time of the Merger, less applicable withholding taxes.  Any outstanding CymaBay stock option with an exercise price equal to or greater than $32.50 was canceled for no consideration."}],"balance_after":0,"derivative":{"exercise_price":7.47,"expiration_date":"2027-09-21","underlying":"Common Stock","underlying_shares":7500},"source":{"system":"sec-edgar","filing":"0000950170-24-035448","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1042074/000095017024035448/ownership.xml","form_type":"4"}},{"id":1563829,"issuer":{"id":92768,"kind":"organization","name":"CymaBay Therapeutics, Inc.","symbol":"CBAY"},"owners":[{"id":20237,"kind":"person","name":"Wills Robert James","position":1,"cik":"0001634189","reported_name":"Wills Robert James","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Employee Stock Option (right to buy)","published_at":"2024-03-22T16:55:35.000Z","date":"2024-03-22","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":15000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Pursuant to the Merger Agreement, each outstanding CymaBay stock option, whether or not vested, was cancelled and converted into the right to receive a cash payment equal to the product of (a) the excess of (i) $32.50 over (ii) the per share exercise price of such stock option, and (b) the total number of shares of CymaBay common stock subject to such stock option immediately prior to the effective time of the Merger, less applicable withholding taxes.  Any outstanding CymaBay stock option with an exercise price equal to or greater than $32.50 was canceled for no consideration."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Pursuant to the Merger Agreement, each outstanding CymaBay stock option, whether or not vested, was cancelled and converted into the right to receive a cash payment equal to the product of (a) the excess of (i) $32.50 over (ii) the per share exercise price of such stock option, and (b) the total number of shares of CymaBay common stock subject to such stock option immediately prior to the effective time of the Merger, less applicable withholding taxes.  Any outstanding CymaBay stock option with an exercise price equal to or greater than $32.50 was canceled for no consideration."}],"balance_after":0,"derivative":{"exercise_price":5.5,"expiration_date":"2027-06-27","underlying":"Common Stock","underlying_shares":15000},"source":{"system":"sec-edgar","filing":"0000950170-24-035448","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1042074/000095017024035448/ownership.xml","form_type":"4"}},{"id":1563828,"issuer":{"id":92768,"kind":"organization","name":"CymaBay Therapeutics, Inc.","symbol":"CBAY"},"owners":[{"id":20237,"kind":"person","name":"Wills Robert James","position":1,"cik":"0001634189","reported_name":"Wills Robert James","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Employee Stock Option (right to buy)","published_at":"2024-03-22T16:55:35.000Z","date":"2024-03-22","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":27000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Pursuant to the Merger Agreement, each outstanding CymaBay stock option, whether or not vested, was cancelled and converted into the right to receive a cash payment equal to the product of (a) the excess of (i) $32.50 over (ii) the per share exercise price of such stock option, and (b) the total number of shares of CymaBay common stock subject to such stock option immediately prior to the effective time of the Merger, less applicable withholding taxes.  Any outstanding CymaBay stock option with an exercise price equal to or greater than $32.50 was canceled for no consideration."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Pursuant to the Merger Agreement, each outstanding CymaBay stock option, whether or not vested, was cancelled and converted into the right to receive a cash payment equal to the product of (a) the excess of (i) $32.50 over (ii) the per share exercise price of such stock option, and (b) the total number of shares of CymaBay common stock subject to such stock option immediately prior to the effective time of the Merger, less applicable withholding taxes.  Any outstanding CymaBay stock option with an exercise price equal to or greater than $32.50 was canceled for no consideration."}],"balance_after":0,"derivative":{"exercise_price":3.48,"expiration_date":"2027-04-26","underlying":"Common Stock","underlying_shares":27000},"source":{"system":"sec-edgar","filing":"0000950170-24-035448","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1042074/000095017024035448/ownership.xml","form_type":"4"}},{"id":1563827,"issuer":{"id":92768,"kind":"organization","name":"CymaBay Therapeutics, Inc.","symbol":"CBAY"},"owners":[{"id":20237,"kind":"person","name":"Wills Robert James","position":1,"cik":"0001634189","reported_name":"Wills Robert James","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Employee Stock Option (right to buy)","published_at":"2024-03-22T16:55:35.000Z","date":"2024-03-22","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":9000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Pursuant to the Merger Agreement, each outstanding CymaBay stock option, whether or not vested, was cancelled and converted into the right to receive a cash payment equal to the product of (a) the excess of (i) $32.50 over (ii) the per share exercise price of such stock option, and (b) the total number of shares of CymaBay common stock subject to such stock option immediately prior to the effective time of the Merger, less applicable withholding taxes.  Any outstanding CymaBay stock option with an exercise price equal to or greater than $32.50 was canceled for no consideration."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Pursuant to the Merger Agreement, each outstanding CymaBay stock option, whether or not vested, was cancelled and converted into the right to receive a cash payment equal to the product of (a) the excess of (i) $32.50 over (ii) the per share exercise price of such stock option, and (b) the total number of shares of CymaBay common stock subject to such stock option immediately prior to the effective time of the Merger, less applicable withholding taxes.  Any outstanding CymaBay stock option with an exercise price equal to or greater than $32.50 was canceled for no consideration."}],"balance_after":0,"derivative":{"exercise_price":1.72,"expiration_date":"2026-06-27","underlying":"Common Stock","underlying_shares":9000},"source":{"system":"sec-edgar","filing":"0000950170-24-035448","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1042074/000095017024035448/ownership.xml","form_type":"4"}},{"id":1563826,"issuer":{"id":92768,"kind":"organization","name":"CymaBay Therapeutics, Inc.","symbol":"CBAY"},"owners":[{"id":20237,"kind":"person","name":"Wills Robert James","position":1,"cik":"0001634189","reported_name":"Wills Robert James","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Employee Stock Option (right to buy)","published_at":"2024-03-22T16:55:35.000Z","date":"2024-03-22","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":25000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Pursuant to the Merger Agreement, each outstanding CymaBay stock option, whether or not vested, was cancelled and converted into the right to receive a cash payment equal to the product of (a) the excess of (i) $32.50 over (ii) the per share exercise price of such stock option, and (b) the total number of shares of CymaBay common stock subject to such stock option immediately prior to the effective time of the Merger, less applicable withholding taxes.  Any outstanding CymaBay stock option with an exercise price equal to or greater than $32.50 was canceled for no consideration."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Pursuant to the Merger Agreement, each outstanding CymaBay stock option, whether or not vested, was cancelled and converted into the right to receive a cash payment equal to the product of (a) the excess of (i) $32.50 over (ii) the per share exercise price of such stock option, and (b) the total number of shares of CymaBay common stock subject to such stock option immediately prior to the effective time of the Merger, less applicable withholding taxes.  Any outstanding CymaBay stock option with an exercise price equal to or greater than $32.50 was canceled for no consideration."}],"balance_after":0,"derivative":{"exercise_price":2.04,"expiration_date":"2025-10-05","underlying":"Common Stock","underlying_shares":25000},"source":{"system":"sec-edgar","filing":"0000950170-24-035448","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1042074/000095017024035448/ownership.xml","form_type":"4"}},{"id":1563825,"issuer":{"id":92768,"kind":"organization","name":"CymaBay Therapeutics, Inc.","symbol":"CBAY"},"owners":[{"id":20237,"kind":"person","name":"Wills Robert James","position":1,"cik":"0001634189","reported_name":"Wills Robert James","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Employee Stock Option (right to buy)","published_at":"2024-03-22T16:55:35.000Z","date":"2024-03-22","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":18000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Pursuant to the Merger Agreement, each outstanding CymaBay stock option, whether or not vested, was cancelled and converted into the right to receive a cash payment equal to the product of (a) the excess of (i) $32.50 over (ii) the per share exercise price of such stock option, and (b) the total number of shares of CymaBay common stock subject to such stock option immediately prior to the effective time of the Merger, less applicable withholding taxes.  Any outstanding CymaBay stock option with an exercise price equal to or greater than $32.50 was canceled for no consideration."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Pursuant to the Merger Agreement, each outstanding CymaBay stock option, whether or not vested, was cancelled and converted into the right to receive a cash payment equal to the product of (a) the excess of (i) $32.50 over (ii) the per share exercise price of such stock option, and (b) the total number of shares of CymaBay common stock subject to such stock option immediately prior to the effective time of the Merger, less applicable withholding taxes.  Any outstanding CymaBay stock option with an exercise price equal to or greater than $32.50 was canceled for no consideration."}],"balance_after":0,"derivative":{"exercise_price":5.9,"expiration_date":"2025-04-15","underlying":"Common Stock","underlying_shares":18000},"source":{"system":"sec-edgar","filing":"0000950170-24-035448","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1042074/000095017024035448/ownership.xml","form_type":"4"}},{"id":1563824,"issuer":{"id":92768,"kind":"organization","name":"CymaBay Therapeutics, Inc.","symbol":"CBAY"},"owners":[{"id":20237,"kind":"person","name":"Wills Robert James","position":1,"cik":"0001634189","reported_name":"Wills Robert James","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-03-22T16:55:35.000Z","date":"2024-03-22","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":30000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Pursuant to the Agreement and Plan of Merger, dated as of February 11, 2024 (the \"Merger Agreement\"), by and among CymaBay Therapeutics, Inc. (\"CymaBay\"), Gilead Sciences, Inc., a Delaware corporation (\"Gilead\"), and Pacific Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Gilead (\"Purchaser\"), among other things, Purchaser merged with and into the Company (the \"Merger\").  Accordingly, each outstanding share of CymaBay common stock was converted into the right to receive a cash payment equal to $32.50, less applicable withholding taxes."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0000950170-24-035448","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1042074/000095017024035448/ownership.xml","form_type":"4"}},{"id":1615235,"issuer":{"id":89585,"kind":"organization","name":"Oncternal Therapeutics, Inc.","symbol":"ONCT"},"owners":[{"id":20237,"kind":"person","name":"Wills Robert James","position":1,"cik":"0001634189","reported_name":"Wills Robert James","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-02-27T17:02:41.000Z","date":"2024-02-23","kind":"sale","planned":false,"acquired":false,"shares":980,"price":9.04,"value":8859.2,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The shares of common stock were sold directly to another director of the Issuer, David F. Hale, and an affiliated entity of Mr. Hale in a private sale. The price per share was based on the closing price of the Issuer's common stock on February 23, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The shares of common stock were sold directly to another director of the Issuer, David F. Hale, and an affiliated entity of Mr. Hale in a private sale. The price per share was based on the closing price of the Issuer's common stock on February 23, 2024."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001209191-24-004015","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1260990/000120919124004015/doc4.xml","form_type":"4"}},{"id":1669902,"issuer":{"id":92768,"kind":"organization","name":"CymaBay Therapeutics, Inc.","symbol":"CBAY"},"owners":[{"id":20237,"kind":"person","name":"Wills Robert James","position":1,"cik":"0001634189","reported_name":"Wills Robert James","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2024-01-26T18:20:42.000Z","date":"2024-01-24","kind":"grant","planned":false,"acquired":true,"shares":14010,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests as to 1/12 of the underlying shares monthly from January 1, 2024."}],"balance_after":14010,"derivative":{"exercise_price":22.85,"expiration_date":"2034-01-23","underlying":"Common Stock","underlying_shares":14010},"source":{"system":"sec-edgar","filing":"0001062993-24-001422","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1042074/000106299324001422/form4.xml","form_type":"4"}},{"id":1840940,"issuer":{"id":89585,"kind":"organization","name":"Oncternal Therapeutics, Inc.","symbol":"ONCT"},"owners":[{"id":20237,"kind":"person","name":"Wills Robert James","position":1,"cik":"0001634189","reported_name":"Wills Robert James","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Options","published_at":"2023-06-30T16:00:18.000Z","date":"2023-06-28","kind":"grant","planned":false,"acquired":true,"shares":25000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"One-twelfth of the number of shares subject to the option vest and become exercisable in substantially equal installments on each monthly anniversary of the grant date, subject to the Reporting Person's continued service through such vesting date."}],"balance_after":25000,"derivative":{"exercise_price":0.3553,"expiration_date":"2033-06-28","underlying":"Common Stock","underlying_shares":25000},"source":{"system":"sec-edgar","filing":"0001209191-23-040282","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1260990/000120919123040282/doc4.xml","form_type":"4"}},{"id":1860149,"issuer":{"id":6561,"kind":"organization","name":"Milestone Pharmaceuticals Inc."},"owners":[{"id":20237,"kind":"person","name":"Wills Robert James","position":1,"cik":"0001634189","reported_name":"Wills Robert James","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2023-06-09T20:23:09.000Z","date":"2023-06-07","kind":"grant","planned":false,"acquired":true,"shares":30000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option will vest in twelve (12) equal monthly installments, beginning on July 7, 2023, provided that the option will in any case be fully vested on the date of next annual meeting of the stockholders of the Issuer, subject to the Reporting Person continuing to provide service through each such vesting date."}],"balance_after":30000,"derivative":{"exercise_price":3.86,"expiration_date":"2033-06-07","underlying":"Common Shares","underlying_shares":30000},"source":{"system":"sec-edgar","filing":"0001209191-23-035844","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1408443/000120919123035844/doc4.xml","form_type":"4"}},{"id":2043971,"issuer":{"id":92768,"kind":"organization","name":"CymaBay Therapeutics, Inc.","symbol":"CBAY"},"owners":[{"id":20237,"kind":"person","name":"Wills Robert James","position":1,"cik":"0001634189","reported_name":"Wills Robert James","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2023-01-27T16:33:53.000Z","date":"2023-01-25","kind":"grant","acquired":true,"shares":25000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests as to 1/12 of the underlying shares monthly from January 1, 2023."}],"balance_after":25000,"derivative":{"exercise_price":7.8,"expiration_date":"2033-01-24","underlying":"Common Stock","underlying_shares":25000},"source":{"system":"sec-edgar","filing":"0001062993-23-001496","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1042074/000106299323001496/form4.xml","form_type":"4"}},{"id":2133399,"issuer":{"id":6561,"kind":"organization","name":"Milestone Pharmaceuticals Inc."},"owners":[{"id":20237,"kind":"person","name":"Wills Robert James","position":1,"cik":"0001634189","reported_name":"Wills Robert James","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Shares","published_at":"2022-10-21T23:03:38.000Z","date":"2022-10-19","kind":"purchase","acquired":true,"shares":15000,"price":4.93,"value":73950.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $4.89 to $4.9494 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote."}],"balance_after":15000,"source":{"system":"sec-edgar","filing":"0001209191-22-054328","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1408443/000120919122054328/doc4.xml","form_type":"4"}},{"id":2187862,"issuer":{"id":6561,"kind":"organization","name":"Milestone Pharmaceuticals Inc."},"owners":[{"id":20237,"kind":"person","name":"Wills Robert James","position":1,"cik":"0001634189","reported_name":"Wills Robert James","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2022-08-11T22:02:27.000Z","date":"2022-07-05","kind":"grant","acquired":true,"shares":30000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option will vest in twelve (12) equal monthly installments, beginning on August 5, 2022, provided that the option will in any case be fully vested\non the date of next annual meeting of the stockholders of the Issuer, subject to the Reporting Person continuing to provide service through each\nsuch vesting date."}],"balance_after":30000,"derivative":{"exercise_price":6.07,"expiration_date":"2032-07-05","underlying":"Common Shares","underlying_shares":30000},"source":{"system":"sec-edgar","filing":"0001209191-22-045472","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1408443/000120919122045472/doc4.xml","form_type":"4"}},{"id":2227323,"issuer":{"id":89585,"kind":"organization","name":"Oncternal Therapeutics, Inc.","symbol":"ONCT"},"owners":[{"id":20237,"kind":"person","name":"Wills Robert James","position":1,"cik":"0001634189","reported_name":"Wills Robert James","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Options","published_at":"2022-06-17T18:00:25.000Z","date":"2022-06-16","kind":"grant","acquired":true,"shares":25000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"One-twelfth of the number of shares subject to the option vest and become exercisable in substantially equal installments on each monthly anniversary of the grant date, subject to the Reporting Person's continued service through such vesting date."}],"balance_after":25000,"derivative":{"exercise_price":1.08,"expiration_date":"2032-06-16","underlying":"Common Stock","underlying_shares":25000},"source":{"system":"sec-edgar","filing":"0001209191-22-038033","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1260990/000120919122038033/doc4.xml","form_type":"4"}},{"id":2424282,"issuer":{"id":92768,"kind":"organization","name":"CymaBay Therapeutics, Inc.","symbol":"CBAY"},"owners":[{"id":20237,"kind":"person","name":"Wills Robert James","position":1,"cik":"0001634189","reported_name":"Wills Robert James","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2022-01-27T16:51:13.000Z","date":"2022-01-25","kind":"grant","acquired":true,"shares":67000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests as to 1/12 of the underlying shares monthly from January 1, 2022."}],"balance_after":67000,"derivative":{"exercise_price":2.94,"expiration_date":"2032-01-24","underlying":"Common Stock","underlying_shares":67000},"source":{"system":"sec-edgar","filing":"0001062993-22-001690","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1042074/000106299322001690/form4.xml","form_type":"4"}},{"id":2621959,"issuer":{"id":6561,"kind":"organization","name":"Milestone Pharmaceuticals Inc."},"owners":[{"id":20237,"kind":"person","name":"Wills Robert James","position":1,"cik":"0001634189","reported_name":"Wills Robert James","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2021-07-29T21:34:49.000Z","date":"2021-06-14","kind":"grant","acquired":true,"shares":30000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option will vest in twelve (12) equal monthly installments, beginning on July 14, 2021, provided that the option will in any case be fully vested on the date of next annual meeting of the stockholders of the Issuer, subject to the Reporting Person continuing to provide service through each such vesting date."}],"balance_after":30000,"derivative":{"exercise_price":5.54,"expiration_date":"2031-06-14","underlying":"Common Shares","underlying_shares":30000},"source":{"system":"sec-edgar","filing":"0001209191-21-048563","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1408443/000120919121048563/doc4.xml","form_type":"4"}},{"id":2692930,"issuer":{"id":89585,"kind":"organization","name":"Oncternal Therapeutics, Inc.","symbol":"ONCT"},"owners":[{"id":20237,"kind":"person","name":"Wills Robert James","position":1,"cik":"0001634189","reported_name":"Wills Robert James","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Options","published_at":"2021-05-27T18:12:17.000Z","date":"2021-05-25","kind":"grant","acquired":true,"shares":25000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"One-twelfth of the number of shares subject to the option vest and become exercisable in substantially equal installments on each monthly anniversary of the grant date, subject to the Reporting Person's continued service on the board of directors of the Issuer through such vesting date."}],"balance_after":25000,"derivative":{"exercise_price":5.14,"expiration_date":"2031-05-25","underlying":"Common Stock","underlying_shares":25000},"source":{"system":"sec-edgar","filing":"0001209191-21-036324","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1260990/000120919121036324/doc4.xml","form_type":"4"}},{"id":2892500,"issuer":{"id":92768,"kind":"organization","name":"CymaBay Therapeutics, Inc.","symbol":"CBAY"},"owners":[{"id":20237,"kind":"person","name":"Wills Robert James","position":1,"cik":"0001634189","reported_name":"Wills Robert James","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2021-01-28T15:01:32.000Z","date":"2021-01-26","kind":"grant","acquired":true,"shares":32000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests as to 1/12 of the underlying shares monthly from January 1, 2021."}],"balance_after":32000,"derivative":{"exercise_price":5.78,"expiration_date":"2031-01-25","underlying":"Common Stock","underlying_shares":32000},"source":{"system":"sec-edgar","filing":"0001333277-21-000026","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1042074/000133327721000026/edgar.xml","form_type":"4"}},{"id":3012563,"issuer":{"id":6561,"kind":"organization","name":"Milestone Pharmaceuticals Inc."},"owners":[{"id":20237,"kind":"person","name":"Wills Robert James","position":1,"cik":"0001634189","reported_name":"Wills Robert James","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2020-10-05T22:02:15.000Z","date":"2020-10-01","kind":"grant","acquired":true,"shares":30000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option will vest in equal monthly installments, beginning on November 1, 2020, over a period of three years, subject to the Reporting Person continuing to provide service through each such vesting date."}],"balance_after":30000,"derivative":{"exercise_price":7.1,"expiration_date":"2030-10-01","underlying":"Common Shares","underlying_shares":30000},"source":{"system":"sec-edgar","filing":"0001209191-20-053842","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1408443/000120919120053842/doc4.xml","form_type":"4"}},{"id":3072380,"issuer":{"id":89585,"kind":"organization","name":"Oncternal Therapeutics, Inc.","symbol":"ONCT"},"owners":[{"id":20237,"kind":"person","name":"Wills Robert James","position":1,"cik":"0001634189","reported_name":"Wills Robert James","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Options","published_at":"2020-07-31T21:06:24.000Z","date":"2019-09-12","kind":"grant","acquired":true,"shares":30000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The original Form 4 reported the acquisition of the Stock Options in the \"D\" column of Column 5.  This amendment is being filed to correctly report the acquisition of the Stock Options in the \"A\" column of Column 5."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"One thirty-sixth of each Effective Date Award and each Initial Award shall vest and become exercisable in substantially equal installments on each monthly anniversary of the date of grant, so that the options subject to each such type of award shall be fully vested on the three-year anniversary of the date of grant, subject to the Reporting Persons continued service on the Board through each such vesting date."}],"balance_after":30000,"derivative":{"exercise_price":5.76,"expiration_date":"2029-09-12","underlying":"Common Stock","underlying_shares":30000},"source":{"system":"sec-edgar","filing":"0001209191-20-044389","document":"doc4a.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1260990/000120919120044389/doc4a.xml","form_type":"4/A","original_submission_date":"2019-09-16"}},{"id":3072378,"issuer":{"id":89585,"kind":"organization","name":"Oncternal Therapeutics, Inc.","symbol":"ONCT"},"owners":[{"id":20237,"kind":"person","name":"Wills Robert James","position":1,"cik":"0001634189","reported_name":"Wills Robert James","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option","published_at":"2020-07-31T21:06:17.000Z","date":"2020-06-11","kind":"grant","acquired":true,"shares":15000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The original Form 4 reported the acquisition of the Stock Options in the \"D\" column of Column 5.  This amendment is being filed to correctly report the acquisition of the Stock Options in the \"A\" column of Column 5."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"One-twelfth of the number of shares subject to the option vest and become exercisable in substantially equal installments on each monthly anniversary of grant date, subject to the Reporting Person's continued service on the board of directors of the Issuer through such vesting date."}],"balance_after":15000,"derivative":{"exercise_price":2.94,"expiration_date":"2030-06-11","underlying":"Common Stock","underlying_shares":15000},"source":{"system":"sec-edgar","filing":"0001209191-20-044386","document":"doc4a.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1260990/000120919120044386/doc4a.xml","form_type":"4/A","original_submission_date":"2018-06-12"}},{"id":3111602,"issuer":{"id":89585,"kind":"organization","name":"Oncternal Therapeutics, Inc.","symbol":"ONCT"},"owners":[{"id":20237,"kind":"person","name":"Wills Robert James","position":1,"cik":"0001634189","reported_name":"Wills Robert James","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Options","published_at":"2020-06-12T16:42:25.000Z","date":"2020-06-11","kind":"grant","acquired":false,"shares":15000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"One-twelfth of  the number of shares subject to the option vest and become exercisable in substantially equal installments on each monthly anniversary of the grant date, subject to the Reporting Person's continued service on the board of directors of the Issuer through such vesting date."}],"balance_after":15000,"derivative":{"exercise_price":2.94,"expiration_date":"2029-06-10","underlying":"Common Stock","underlying_shares":15000},"source":{"system":"sec-edgar","filing":"0001209191-20-036309","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1260990/000120919120036309/doc4.xml","form_type":"4"}},{"id":3143412,"issuer":{"id":92768,"kind":"organization","name":"CymaBay Therapeutics, Inc.","symbol":"CBAY"},"owners":[{"id":20237,"kind":"person","name":"Wills Robert James","position":1,"cik":"0001634189","reported_name":"Wills Robert James","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2020-05-19T17:19:20.000Z","date":"2020-05-15","kind":"grant","acquired":true,"shares":49245,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the option shall vest in 12 equal monthly installments commencing on January 31, 2020, subject to the Reporting Person's continuous service to the Issuer as of each such date."}],"balance_after":49245,"derivative":{"exercise_price":4.05,"expiration_date":"2030-05-14","underlying":"Common Stock","underlying_shares":49245},"source":{"system":"sec-edgar","filing":"0001209191-20-030592","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1042074/000120919120030592/doc4.xml","form_type":"4"}},{"id":3413742,"issuer":{"id":89585,"kind":"organization","name":"Oncternal Therapeutics, Inc.","symbol":"ONCT"},"owners":[{"id":20237,"kind":"person","name":"Wills Robert James","position":1,"cik":"0001634189","reported_name":"Wills Robert James","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option","published_at":"2019-09-16T17:44:53.000Z","date":"2019-09-12","kind":"grant","acquired":false,"shares":30000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"One thirty-sixth of each Effective Date Award and each Initial Award shall vest and become exercisable in substantially equal installments on each monthly anniversary of the date of grant, so that the options subject to each such type of award shall be fully vested on the three-year anniversary of the date of grant, subject to the Reporting Persons continued service on the Board through each such vesting date."}],"balance_after":30000,"derivative":{"exercise_price":5.76,"expiration_date":"2029-09-12","underlying":"Common Stock","underlying_shares":30000},"source":{"system":"sec-edgar","filing":"0001209191-19-049698","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1260990/000120919119049698/doc4.xml","form_type":"4"}},{"id":3681494,"issuer":{"id":92768,"kind":"organization","name":"CymaBay Therapeutics, Inc.","symbol":"CBAY"},"owners":[{"id":20237,"kind":"person","name":"Wills Robert James","position":1,"cik":"0001634189","reported_name":"Wills Robert James","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2019-01-31T17:24:16.000Z","date":"2019-01-29","kind":"grant","acquired":true,"shares":27705,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests as to 1/12 of the underlying shares monthly from January 1, 2019."}],"balance_after":27705,"derivative":{"exercise_price":8.43,"expiration_date":"2029-01-28","underlying":"Common Stock","underlying_shares":27705},"source":{"system":"sec-edgar","filing":"0001333277-19-000025","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1042074/000133327719000025/edgar.xml","form_type":"4"}},{"id":3882936,"issuer":{"id":89585,"kind":"organization","name":"Oncternal Therapeutics, Inc.","symbol":"ONCT"},"owners":[{"id":20237,"kind":"person","name":"Wills Robert James","position":1,"cik":"0001634189","reported_name":"Wills Robert James","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Executive Chairman"}}],"security":"Common Stock","published_at":"2018-06-26T11:21:40.000Z","date":"2018-06-26","kind":"purchase","acquired":true,"shares":5000,"price":16.75,"value":83750.0,"ownership":{"direct":true},"balance_after":137344,"source":{"system":"sec-edgar","filing":"0001179110-18-009039","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1260990/000117911018009039/edgar.xml","form_type":"4"}},{"id":4088454,"issuer":{"id":92768,"kind":"organization","name":"CymaBay Therapeutics, Inc.","symbol":"CBAY"},"owners":[{"id":20237,"kind":"person","name":"Wills Robert James","position":1,"cik":"0001634189","reported_name":"Wills Robert James","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2018-01-26T17:47:11.000Z","date":"2018-01-24","kind":"grant","acquired":true,"shares":16000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests as to 1/12 of the underlying shares monthly beginning January 1, 2018."}],"balance_after":16000,"derivative":{"exercise_price":11.69,"expiration_date":"2028-01-23","underlying":"Common Stock","underlying_shares":16000},"source":{"system":"sec-edgar","filing":"0001333277-18-000033","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1042074/000133327718000033/edgar.xml","form_type":"4"}},{"id":4111034,"issuer":{"id":89585,"kind":"organization","name":"Oncternal Therapeutics, Inc.","symbol":"ONCT"},"owners":[{"id":20237,"kind":"person","name":"Wills Robert James","position":1,"cik":"0001634189","reported_name":"Wills Robert James","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Executive Chairman"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2018-01-03T18:27:17.000Z","date":"2018-01-01","kind":"grant","acquired":true,"shares":65000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests and is exercisable in 3 equal annual installments beginning January 1, 2021."}],"balance_after":65000,"derivative":{"exercise_price":12.71,"expiration_date":"2027-12-31","underlying":"Common Stock","underlying_shares":65000},"source":{"system":"sec-edgar","filing":"0001179110-18-000407","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1260990/000117911018000407/edgar.xml","form_type":"4"}},{"id":4201684,"issuer":{"id":92768,"kind":"organization","name":"CymaBay Therapeutics, Inc.","symbol":"CBAY"},"owners":[{"id":20237,"kind":"person","name":"Wills Robert James","position":1,"cik":"0001634189","reported_name":"Wills Robert James","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2017-09-26T09:40:58.000Z","date":"2017-09-22","kind":"grant","acquired":true,"shares":7500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the option shall vest in 12 equal monthly installments commencing on June 1, 2017, subject to the Reporting Person's continuous service to the Issuer as of each such date. The option allows for early exercise by the Reporting Person."}],"balance_after":7500,"derivative":{"exercise_price":7.47,"expiration_date":"2027-09-21","underlying":"Common Stock","underlying_shares":7500},"source":{"system":"sec-edgar","filing":"0001209191-17-053903","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1042074/000120919117053903/doc4.xml","form_type":"4"}},{"id":4246072,"issuer":{"id":92768,"kind":"organization","name":"CymaBay Therapeutics, Inc.","symbol":"CBAY"},"owners":[{"id":20237,"kind":"person","name":"Wills Robert James","position":1,"cik":"0001634189","reported_name":"Wills Robert James","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2017-08-02T08:21:17.000Z","date":"2017-08-01","kind":"purchase","acquired":true,"shares":3500,"price":6.847,"value":23964.5,"ownership":{"direct":true},"balance_after":30000,"source":{"system":"sec-edgar","filing":"0001209191-17-047016","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1042074/000120919117047016/doc4.xml","form_type":"4"}},{"id":4246071,"issuer":{"id":92768,"kind":"organization","name":"CymaBay Therapeutics, Inc.","symbol":"CBAY"},"owners":[{"id":20237,"kind":"person","name":"Wills Robert James","position":1,"cik":"0001634189","reported_name":"Wills Robert James","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2017-08-02T08:21:17.000Z","date":"2017-08-01","kind":"purchase","acquired":true,"shares":1000,"price":6.839,"value":6839.0,"ownership":{"direct":true},"balance_after":26500,"source":{"system":"sec-edgar","filing":"0001209191-17-047016","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1042074/000120919117047016/doc4.xml","form_type":"4"}},{"id":4246070,"issuer":{"id":92768,"kind":"organization","name":"CymaBay Therapeutics, Inc.","symbol":"CBAY"},"owners":[{"id":20237,"kind":"person","name":"Wills Robert James","position":1,"cik":"0001634189","reported_name":"Wills Robert James","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2017-08-02T08:21:17.000Z","date":"2017-08-01","kind":"purchase","acquired":true,"shares":300,"price":6.838,"value":2051.4,"ownership":{"direct":true},"balance_after":25500,"source":{"system":"sec-edgar","filing":"0001209191-17-047016","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1042074/000120919117047016/doc4.xml","form_type":"4"}},{"id":4246069,"issuer":{"id":92768,"kind":"organization","name":"CymaBay Therapeutics, Inc.","symbol":"CBAY"},"owners":[{"id":20237,"kind":"person","name":"Wills Robert James","position":1,"cik":"0001634189","reported_name":"Wills Robert James","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2017-08-02T08:21:17.000Z","date":"2017-08-01","kind":"purchase","acquired":true,"shares":200,"price":6.829,"value":1365.8,"ownership":{"direct":true},"balance_after":25200,"source":{"system":"sec-edgar","filing":"0001209191-17-047016","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1042074/000120919117047016/doc4.xml","form_type":"4"}},{"id":4269479,"issuer":{"id":92768,"kind":"organization","name":"CymaBay Therapeutics, Inc.","symbol":"CBAY"},"owners":[{"id":20237,"kind":"person","name":"Wills Robert James","position":1,"cik":"0001634189","reported_name":"Wills Robert James","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2017-06-30T14:47:16.000Z","date":"2017-06-28","kind":"grant","acquired":true,"shares":15000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the option shall vest in 12 equal monthly installments commencing on June 1, 2017."}],"balance_after":15000,"derivative":{"exercise_price":5.5,"expiration_date":"2027-06-27","underlying":"Common Stock","underlying_shares":15000},"source":{"system":"sec-edgar","filing":"0001042074-17-000015","document":"primary_doc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1042074/000104207417000015/primary_doc.xml","form_type":"4"}},{"id":4340613,"issuer":{"id":92768,"kind":"organization","name":"CymaBay Therapeutics, Inc.","symbol":"CBAY"},"owners":[{"id":20237,"kind":"person","name":"Wills Robert James","position":1,"cik":"0001634189","reported_name":"Wills Robert James","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2017-05-01T19:50:21.000Z","date":"2017-04-27","kind":"grant","acquired":true,"shares":27000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests in equal monthly installments over the eight-month period beginning on the vesting commencement date of April 15, 2017, subject to the Reporting Person's continuous service to the Issuer; provided, however, that this option will stop vesting on the date the Reporting Person resigns as the Executive Chairman of the Issuer, but continue to serve as the director of the Issuer."}],"balance_after":27000,"derivative":{"exercise_price":3.48,"expiration_date":"2027-04-26","underlying":"Common Stock","underlying_shares":27000},"source":{"system":"sec-edgar","filing":"0001179110-17-006331","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1042074/000117911017006331/edgar.xml","form_type":"4"}},{"id":4408915,"issuer":{"id":89585,"kind":"organization","name":"Oncternal Therapeutics, Inc.","symbol":"ONCT"},"owners":[{"id":20237,"kind":"person","name":"Wills Robert James","position":1,"cik":"0001634189","reported_name":"Wills Robert James","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Executive Chairman"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2017-03-02T16:56:22.000Z","date":"2017-02-28","kind":"grant","acquired":true,"shares":95000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests and is exercisable in 3 equal annual installments beginning February 28, 2020."}],"balance_after":95000,"derivative":{"exercise_price":4.71,"expiration_date":"2027-02-27","underlying":"Common Stock","underlying_shares":95000},"source":{"system":"sec-edgar","filing":"0001179110-17-003651","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1260990/000117911017003651/edgar.xml","form_type":"4"}},{"id":4578923,"issuer":{"id":89585,"kind":"organization","name":"Oncternal Therapeutics, Inc.","symbol":"ONCT"},"owners":[{"id":20237,"kind":"person","name":"Wills Robert James","position":1,"cik":"0001634189","reported_name":"Wills Robert James","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Executive Chairman"}}],"security":"Common Stock","published_at":"2016-10-17T16:17:15.000Z","date":"2016-10-14","kind":"grant","acquired":true,"shares":123456,"price":0.81,"value":99999.36,"ownership":{"direct":true},"balance_after":1323456,"source":{"system":"sec-edgar","filing":"0001179110-16-030747","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1260990/000117911016030747/edgar.xml","form_type":"4"}},{"id":4606894,"issuer":{"id":92768,"kind":"organization","name":"CymaBay Therapeutics, Inc.","symbol":"CBAY"},"owners":[{"id":20237,"kind":"person","name":"Wills Robert James","position":1,"cik":"0001634189","reported_name":"Wills Robert James","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2016-09-09T08:05:00.000Z","date":"2016-09-06","kind":"purchase","acquired":true,"shares":25000,"price":2.4343,"value":60857.5,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price.  These shares were sold in multiple transactions at prices ranging from $2.37 to $2.46, inclusive.  The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range."}],"balance_after":25000,"source":{"system":"sec-edgar","filing":"0001179110-16-029465","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1042074/000117911016029465/edgar.xml","form_type":"4"}}]}